Skip to main content
STRO
NASDAQ Life Sciences

Sutro 10-Q: Q3 Revenue $9.1M Misses, Cash $142.2M Funds Runway Into 1H 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.59
Mkt Cap
$159.013M
52W Low
$7.15
52W High
$43.85
52W Position info
34% above low
Off High info
78% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

STRO sits 34% above its 52-week low of $7.15 on elevated volume (2.2× avg).

Summary

Sutro's Q3 10-Q confirms the already-reported $9.1 million revenue and shows $142.2 million in cash and securities at September 30, down from $164.3 million at June 30, with runway stated into the first half of 2028.


Key Events · Earnings and Guidance · STRO

  • Q3 Revenue $9.1M, Down 6% Year Over Year

    Revenue was $9.098 million for the quarter ended September 30, 2026 versus $9.693 million a year earlier, a $0.6 million decline driven mainly by lower Astellas research and materials supply.

  • Cash Falls to $142.2M From $164.3M

    Cash, cash equivalents and marketable securities totaled $142.2 million at September 30, 2026, down from $164.3 million at June 30, 2026; management states this funds operations for at least twelve months from the filing date.

  • $5.7M Revenue Catch-Up Cut on Astellas Effort

    Higher estimated FTE effort to complete Astellas work produced a $5.7 million downward cumulative catch-up, increasing net loss by $5.7 million and net loss per share by $0.34 for the quarter and $0.37 for the nine months.

  • Net Loss $31.5M for the Quarter

    Net loss was $31.489 million for Q3 2026 versus $56.857 million a year earlier, and $108.506 million for the nine months versus $144.324 million, as restructuring cut operating expenses 47% year over year.


Analysis · STRO · Life Sciences

The headline numbers were already out via this morning's 8-K and press coverage, so the revenue miss itself is not new. What the 10-Q adds is the full balance sheet and cash detail: $142.2 million of cash and securities at September 30, down from $164.3 million at June 30, which management says funds operations for at least twelve months and, per the furnished release, into the first half of 2028. The quarter also carried a $5.7 million downward revenue catch-up from higher estimated effort on the Astellas work, which pushed net loss per share up by $0.34. With a $1.09 billion accumulated deficit and no approved products, the runway and the pace of cash burn are the numbers that matter here.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STRO was trading at $9.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159M. The 52-week trading range was $7.15 to $43.85. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STRO - Latest Insights

STRO
Nov 12, 2026, 4:31 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.59
Real-time Price: $9.59 info
Change: $0 (0%) info
Market Cap: $159.013M info
STRO
Aug 12, 2026, 2:04 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $21.83
Real-time Price: $9.59 info
Change: -$12.24 (-56%) info
Market Cap: $159.013M info
STRO
Aug 12, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $24.67
Real-time Price: $9.59 info
Change: -$15.08 (-61%) info
Market Cap: $159.013M info
STRO
May 14, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $38.42
Real-time Price: $9.59 info
Change: -$28.83 (-75%) info
Market Cap: $159.013M info
STRO
May 14, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $38.42
Real-time Price: $9.59 info
Change: -$28.83 (-75%) info
Market Cap: $159.013M info